Skip to content

A Brief Self-compassion Intervention for Body Image, Minority Stress, and Sexual Self-efficacy in Hong Kong Gay Men

A Brief Self-compassion Intervention for Body Image, Minority Stress, and Sexual Self-efficacy in Hong Kong Gay Men

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07369661
Enrollment
20
Registered
2026-01-27
Start date
2026-04-27
Completion date
2026-08-28
Last updated
2026-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gay Men

Keywords

gay men, self-compassion, body image, mental health

Brief summary

This pilot study aims to explore the feasibility, acceptability, and preliminary effectiveness of a brief self-compassion writing intervention on body image, minority stress, and sexual self-efficacy among gay men in Hong Kong.

Detailed description

Gay men experience greater body dissatisfaction, a stronger drive for muscularity, and heightened body image concerns compared to their heterosexual counterparts. These issues contribute to minority stress, anxiety, low self-esteem, and engagement in risky sexual behaviors. Using a randomized controlled trial (RCT) design, we aim to explore the feasibility, acceptability, and preliminary effectiveness of a brief self-compassion writing intervention on body image, minority stress, and sexual self-efficacy among gay men in Hong Kong.

Interventions

BEHAVIORALBrief self-compassion intervention

Participants will be randomly allocated to the self-compassion group and the waiting list control group. The interveintion group will receive a 2.5 self-compassion training, and 3 week self-compassion writing exercise.

Sponsors

Hong Kong Metropolitan University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Intervention model description

We will include a self-compassion intervention group and a waiting-list control group.

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* aged 18 years or above * self-identified as a gay man * sufficient comprehension of Cantonese * currently living in Hong Kong * able to provide informed consent

Exclusion criteria

* currently experiencing psychosis * having an intellectual disability * experiencing current suicidal ideation * not currently receiving or engaging in regular mental health services in the last 3 months * participation in a similar study or receiving similar services in the past 12 months

Design outcomes

Primary

MeasureTime frameDescription
self-compassionFrom enrollment to the end of intervention at 1 monthSelf-compassion will be measured using the 12-item short version of the self-compassion scale (SCS). Items are rated on a 5-point Likert scale ranging from 1 (Almost Never) to 5 (Almost Always). The total score ranged from 12 to 60, with higher score indicating higher level of self-compassion.

Secondary

MeasureTime frameDescription
Sexuality-based stigmaFrom enrollment to the end of treatment at 1 monthSexuality-based stigma will be measured by the 10-item Chinese men sex with men (MSM) Stigma Scale. Items are rated on a four-point Likert scale from 1 (never) to 4 (many times). The total score ranges from 10 to 40, with higher score indicating higher level of sexuality-based stigma.
Internalized stigmaFrom enrollment to the end of treatment at 1 monthInternalized stigma will be measured with the 5-item revised internalized homophobia scale (IHP-R). Items are measured on a five-point Likert scale between 1 (Strongly Disagree) and 5 (Strongly Agree). The total score ranges from 5 to 25, with higher scores indicate greater internalized stigma.
anxietyFrom enrollment to the end of treatment at 1 monthAnxiety symptoms will be measured using the 7-item Generalized Anxiety Disorder-7 (GAD-7). Items are rated on a 4-point Likert scale ranging from 0 (not at all) to 3 (nearly every day). The total score ranges from 0 to 21, with higher total scores indicating higher levels of anxiety symptoms
self-esteemFrom enrollment to the end of treatment at 1 monthThe 10-item Rosenberg Self-Esteem Scale (RSE) will be used to measured self-esteem. Items will be rated on a 4-point Liker scale (1 = Strongly agree, 4 = Strongly disagree). The total score ranges from 10 to 40, with higher score indicating higher level of self-esteem.
body objectificationFrom enrollment to the end of treatment at 1 monthSelf-objectification will be measured using the Chinese version of the Objectified Body Consciousness Scale (OBCS) - body-surveillance subscale. It consists of eight items rated on a 7-point Likert scale (1 = strongly disagree to 7 = strongly agree). The total score ranges from 7 to 56, with a higher score indicating a higher level of body surveillance.
sexual self-efficacyFrom enrollment to the end of treatment at 1 monthThe 14-item Condom Self-Efficacy Scale (CSES) will be used to measurement participants' sexual self-efficacy. Items will be measured on a 5-point Likert scale, ranging from 1 (very unsure) to 5 (very sure). The total score ranging from 14 to 70, with higher scores indicated a higher level of condom use efficacy.
Body shameFrom enrollment to the end of intervention at 1 monthBody shame will be measured using the Chinese version of the Objectified Body Consciousness Scale (OBCS) - body shame subscale (McKinley \& Hyde, 1996). It consists of six items rated on a 7-point Likert scale (1 = strongly disagree to 7 = strongly agree), with a higher score indicating a higher level of body shame.
DepressionFrom enrollment to the end of intervention at 1 monthDepression will be measured using the Chinese version of the 9-item Patient Health Questionnaire (PHQ-9). Items are rated on a 4-point Likert scale ranging from 0 (not at all) to 3 (nearly every day). The total score ranges from 0 to 27, with higher total scores indicating higher levels of depressive symptoms.

Countries

Hong Kong

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 1, 2026